TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kala Pharmaceuticals ( (KALA) ) has issued an announcement.
On November 10, 2025, KALA BIO, Inc. received a deficiency letter from Nasdaq indicating non-compliance with the Minimum Market Value of Listed Securities Requirement, as its market value was below $35 million for 30 consecutive business days. The company has until May 11, 2026, to regain compliance, failing which it may face delisting. KALA BIO intends to monitor its market value and consider options to meet the Nasdaq requirements.
The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Kala Pharmaceuticals stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about Kala Pharmaceuticals
Average Trading Volume: 1,117,614
Technical Sentiment Signal: Sell
Current Market Cap: $5.13M
For an in-depth examination of KALA stock, go to TipRanks’ Overview page.